CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.
HIV-1 protease inhibitors (PIs) have long been central to antiretroviral therapy, directly targeting the enzyme responsible for processing viral polyproteins into functional units. Their efficacy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback